Charles Schwab’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Charles Schwab’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,492	Closed	-$23K	–	3176
2017 Q1	$23K	Hold	6,492	–	–	﹤0.01%	3051
2016 Q4	$34K	Hold	6,492	–	–	﹤0.01%	3069
2016 Q3	$164K	Hold	6,492	–	–	﹤0.01%	2956
2016 Q2	$161K	Hold	6,492	–	–	﹤0.01%	2997
2016 Q1	$189K	Hold	6,492	–	–	﹤0.01%	2911
2015 Q4	$241K	Hold	6,492	–	–	﹤0.01%	2923
2015 Q3	$317K	Hold	6,492	–	–	﹤0.01%	2804
2015 Q2	$448K	Buy	+6,492	New	+$301K	﹤0.01%	2714

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Charles Schwab's ANTH Position: Q2 2017 in Review

Charles Schwab sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 6,492 shares — an estimated $23K sold.

Charles Schwab first reported a position in ANTH in Q2 2015 and held it in 8 quarters. The position peaked at $448K in Q2 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

Charles Schwab reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Charles Schwab sold 6,492 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $23K.
Charles Schwab first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
Charles Schwab's Anthera Pharmaceuticals, Inc. position peaked at $448K in Q2 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.